Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.70 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110004 | 0.95 | PDE5A (0.64) | PDE5AMAP2K4HTTMEN1KMT2A | |
| SCHEMBL3758609 | 0.86 | PDE5A (0.71) | PDE5AMAP2K4HTTMEN1KMT2A | |
| SCHEMBL7991813 | 0.82 | PDE5A (1.00) | PDE5A | |
| SCHEMBL3755765 | 0.81 | PDE5A (0.65) | PDE5AMAP2K4HTTMEN1KMT2A | |
| SCHEMBL3108720 | 0.79 | MAP2K4 (0.61) | PDE5AMAP2K4HTTMEN1KMT2A | |
| SCHEMBL3121603 | 0.79 | MAP2K4 (0.58) | PDE5AMAP2K4HTTMEN1KMT2A | |
| SCHEMBL3762539 | 0.77 | PDE5A (0.54) | PDE5AMAP2K4HTTMEN1KMT2A | |
| SCHEMBL3760931 | 0.77 | PDE5A (0.54) | PDE5AMAP2K4HTTMEN1KMT2A | |
| SCHEMBL26157986 | 0.74 | PDE5A (0.56) | PDE5AMAP2K4HTTMEN1KMT2A | |
| SCHEMBL3115206 | 0.73 | MAP2K4 (0.54) | PDE5AMAP2K4HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | PDE5A 2924/4885MAP2K4 3850/4885HTT 2744/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PDE5A 3000/4885MAP2K4 3788/4885HTT 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.